Every launch plan has a slide titled “patient advocacy.” It usually contains three logos, a quote from a workshop, and a promise to “engage.” Six months later the same slide is still in circulation, one of the groups has changed leadership, and nobody can say whether they were the right partners for this indication in this country.
That is not a patient advocacy group database. It is a souvenir.
I built PatientGroups.co because brand, medical, and patient-engagement teams kept reconstructing the same landscape by hand. This is the method I wish those teams used even if they never log in.
The job is mapping, then choosing — in that order
Finding groups is easy. Google, a medical affairs contact, the last congress badge scan. The failure is treating the first three names as the landscape.
A usable map answers:
- Which organisations exist for this condition, including the unglamorous ones?
- Where are they (country, language, online-only vs on-the-ground)?
- Who do they actually represent — patients, caregivers, a professional society wearing an advocacy hat?
- How active are they now, not on the “about” page from 2019?
- Who already has a relationship with a competitor, a trial network, or a policy coalition?
Until you can see that, “partnership” is a raffle. Scoring comes after the map, not instead of it.
What people get wrong
Mistaking visibility for legitimacy. The group with the polished site and the congress booth is not always the group with members. Some of the most useful organisations are small, local, and almost invisible in English-language search.
One global list for every affiliate. A UK charity, a US 501(c), and a French association are not interchangeable, even when they share a disease name. Partnership scoring has to be local enough to be true.
Treating a workshop as due diligence. A paid advisory with three attendees is input. It is not a map of the community.
Ignoring independence and funding. You do not need a morality play. You do need to know if the organisation can credibly sit in a room as a patient voice, or if they will be seen as an extension of industry. That affects whether a partnership helps or harms.
Never looking again. Groups form, split, go quiet, get captured, get better. Annual agency reports go stale on the day they are emailed. Monitoring is part of the product, not a nice-to-have.
Using the pharma tool as a patient service. Patients looking for a community need a different thing: a directory they can use tonight. That is PatientGroups.ai. Do not make patients apply through your CRM.
A scoring model that is allowed to be simple
Partnership scoring is not a scientific law. It is a consistent way to compare organisations against a brief. I would rather a simple score everyone understands than a 40-factor black box nobody can defend in a brand meeting.
Dimensions that usually matter:
- Indication fit — do they actually serve this condition, or a huge umbrella that includes it on a footer?
- Geography and language — can they work where you need them?
- Activity — public output, events, community, in a recent window
- Reach vs depth — a large following is not the same as a functioning community
- Independence and governance — enough structure to be a counterpart
- Overlap — already in a competitor’s programme, already in your own
Score against this year’s brief, not against a generic “importance” number. A group that is perfect for a trial-recruitment conversation may be the wrong partner for a policy campaign.
Write the criteria down. Apply them twice, a quarter apart. If the scores swing wildly, your criteria were theatre.
Clinical trials need a different cut of the same map
“How to find patient advocacy groups for clinical trials” is a search I see a lot. The mistake is using the brand-partnership shortlist. Trial support wants groups that can reach the right patients ethically, understand the protocol well enough not to mislead, and are willing to work within what you are allowed to say.
That is a filter on the map, not a separate universe. If your trial list and your brand list were built by two agencies that never shared files, you will double-count some groups and miss the ones that actually sit close to patients.
Monitoring is how the map stays honest
A database that nobody updates is a PDF with extra steps. Minimum viable monitoring:
- Did they still exist last month?
- Did leadership or remit change?
- Did they publish something that affects your indication?
- Did a new group appear that your last search missed?
You do not need a war room. You need a reason to look again before the next planning cycle.
Where PatientGroups.co fits
PatientGroups.co is the B2B product for this: identify, score, monitor. It sits in Phormulate Ltd, next to the free patient-facing directory. I care about that split. Pharma intelligence and patient matching are different duties of care.
If you want the tool: patientgroups.co. If you want a human conversation about how your team currently builds the list, get in touch.